Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267276 | 0.83 | RXRA (0.49) | NR4A2RXRARXRBRXRGPDE10A | |
| SCHEMBL1003345 | 0.79 | MAPT (0.40) | MAPTPKMPDE10AMEN1KMT2A | |
| SCHEMBL1003049 | 0.78 | FAAH (0.63) | FAAH | |
| SCHEMBL1000358 | 0.74 | TSHR (0.48) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL6256 | 0.74 | TSHR (0.48) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL439856 | 0.74 | TSHR (0.48) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL7182 | 0.74 | TSHR (0.48) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL6257 | 0.74 | TSHR (0.48) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL9820889 | 0.72 | MAPT (0.44) | MAPTPKMMEN1ALDH1A1KMT2A | |
| SCHEMBL19182180 | 0.72 | MAPT (0.53) | MAPTPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | MAPT 1377/4885PKM 281/4885FAAH 1/4885 |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | MAPT 1378/4885PKM 343/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.